Skip to Main Content

Hello, everyone, and welcome to another busy day. All EpiPen, all the time, appears to be a new slogan. Nonetheless, the world continues to spin elsewhere, and so we have managed to gather a few other items of interest to help you along. As always, we hope you have a productive day and do keep us in mind when you run across something interesting. Cheers …

Four out of five UK doctors are unable to give patients their first choice of treatment due to drug shortages, PharmaTimes reports, citing a new survey. Of 441 general practitioners queried, 82 percent said shortages had forced them to prescribe a second-choice medicine in the past 12 months, and 18 percent said patients had experienced a negative effect — an adverse event or reduced efficacy — as a result.

For the second consecutive year, California Governor Jerry Brown will have to decide whether to sign into law a so-called Right to Try bill that would allow terminally ill patients access to experimental drugs, the Los Angeles Times reports. He vetoed such a bill last fall. So far, 31 states have passed such laws, and the notion was embraced by the Republican Party in its platform this summer.


Teva Pharmaceuticals suffered a blow Wednesday as the US Patent Trial and Appeal Board invalidated two patents protecting its Copaxone multiple sclerosis drug, which generates 20 percent of revenue, Bloomberg News says. The original version, which has a 20-milligram daily dose, began facing generic competition last year, but Teva has maintained sales by switching about 80 percent of patients to a 40-milligram injection. Teva plans to appeal.

Novartis says a late-stage study showed its oral, once-daily pill for treating multiple sclerosis reduced the risk of disability progression in a severe form of the disease, Reuters writes.


The Drugs Controller General of India has initiated several measures to streamline the process for conducting clinical trials in the country, PharmaBiz tells us.

PharMerica, which manages pharmacies for long-term care facilities, is considering a sale of the company, according to Reuters.

The UK’s National Institute for Health and Care Excellence published two sets of guidelines increasing treatment options for patients with chronic myeloid leukemia and non-small cell lung cancer, PharmaTimes says.

Swiss scientists have found a less expensive method for synthesizing amines, the components used in a variety of active pharmaceutical ingredients, InPharma Technologist writes.

  • Since the ‘Under Fire ..’ post has no comment field, I’ll leave one here under the theme – ‘All EpiPen’ all the time. Based on this comment attributed to Mylans CEO – ‘The company maintains that private insurers too often fail to sufficiently cover the EpiPen..’ – I can see why her MBA was yanked. Insurance co$t$ are still really money. A fact buoyed by the size of her compensation package.

Comments are closed.